Skip to content

Business News

Akeso’s Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA By Investing.com

HONG KONG, Jan. 26, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody… Read More »Akeso’s Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA By Investing.com